Supercharged immune cells take on pancreatic cancer

NCT ID NCT07627711

Recruiting now Disease control Sponsor: Beijing Biotech Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new type of cell therapy for people with advanced pancreatic cancer that has spread or cannot be removed by surgery. The treatment uses specially engineered natural killer (NK) cells that target two proteins found on cancer cells. Up to 42 participants will receive the cells by IV infusion to see if it is safe and can help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dual-targeting CAR-NK cells (engineered immune cells) targeting MSLN and MUC1 or CLDN18.2 and MUC1
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer that is hard to treat with standard therapies.
What could go wrong: This is an early-phase trial with only 42 participants, so results may not apply to everyone. The therapy is experimental and may cause side effects or not shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm Neoplasm Metastasis pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC DISEASE PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) UNRESECTABLE LOCALLY ADVANCED

Contacts and locations

Locations

Peking University Shenzhen Hospital
RECRUITING

Shenzhen, Guangdong, 518036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.